Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention

Gynecologic Oncology

Volumn 138, Issue 2, 2015, Pages 235-237

  Lheureux, Stephanie ^a   Shaw, Patricia A ^b   Karakasis, Katherine ^a   Oza, Amit M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA; Occult carcinoma; Ovarian cancer; STIC; STIL

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

CANCER PATIENT; CANCER PREVENTION; DISEASE MARKER; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; NOTE; OBSTETRIC PATIENT; OCCULT CANCER; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROPHYLACTIC SURGICAL PROCEDURE; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SURGICAL PATIENT; CYSTADENOCARCINOMA, SEROUS; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; PATHOLOGY; PRECANCER; SURGERY; TUMOR SUPPRESSOR GENE; UTERINE TUBE;

CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; PRECANCEROUS CONDITIONS;

EID: 84938198191     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.06.014     Document Type: Editorial

References (15)

1. S.H. George, and P. Shaw BRCA and early events in the development of serous ovarian cancer Front. Oncol. 4 Jan 23 2014 5
2. C.B. Powell Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later Gynecol. Oncol. 132 2 Feb 2014 261 263
3. D. Tsoref, T. Panzarella, and A. Oza Aspirin in prevention of ovarian cancer: are we at the tipping point? J. Natl. Cancer Inst. 106 2 Feb 2014 djt453
4. B.T. Hennessy, K.M. Timms, M.S. Carey, and et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) J. Clin. Oncol. 28 22 Aug 1 2010 3570 3576
5. C. Garcia, J. Wendt, L. Lyon, and et al. Risk management options elected by women after testing positive for a BRCA mutation Gynecol. Oncol. 132 2 Feb 2014 428 433
6. A.L. Gross, R.J. Kurman, R. Vang, IeM Shih, and K. Visvanathan Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics J. Oncol. 2010 2010 126295
7. A. Finch, P.A. Shaw, B. Rosen, J. Murphy, S.A. Narod, and T.J. Colgan Clinical and pathologic findings of prophylactic salpingo-oophorectomies 159 BRCA1 and BRCA2 carriers Gynecol. Oncol. 100 1 2006 58 64
8. C.B. Powell, E. Kenley, L.M. Chen, and et al. Risk reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy J. Clin. Oncol. 23 1 2005 127 132
9. M.J. Callahan, C.P. Crum, F. Medeiros, and et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction J. Clin. Oncol. 25 2007 3985 3990
10. P.A. Shaw, M. Rouzbahman, E.S. Pizer, M. Pintilie, and H. Begley Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers Mod. Pathol. 22 9 Sep 2009 1133 1138
11. D. Vicus, P.A. Shaw, A. Finch, and et al. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers Gynecol. Oncol. 118 3 Sep 2010 295 298
12. D.R. Semmel, A.K. Folkins, M.S. Hirsch, M.R. Nucci, and C.P. Crum Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria Mod. Pathol. 22 8 Aug 2009 985 988
13. F. Medeiros, M.G. Muto, Y. Lee, and et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am. J. Surg. Pathol. 30 2 Feb 2006 230 236
14. K. Visvanathan, R. Vang, P. Shaw, and et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study Am. J. Surg. Pathol. 35 12 Dec 2011 1766 1775
15. R. Vang, K. Visvanathan, A. Gross, and et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma Int. J. Gynecol. Pathol. 31 3 May 2012 243 253